ZHENZHEN LIANG

Dr. ZHENZHEN LIANG

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LHLi Huang
Li Huang
HCHuajian Chen
Huajian Chen
ZLZHENZHEN LIANG
ZHENZHEN LIANG
Frailty is a state that is closely associated with adverse health outcomes in the aging process. The frailty index (FI), which measures frailty in terms of cumulative deficits, has been widely used for frailty assessment in elderly people, and its advantage of self-reported information collection makes it applicable to a broader group of elderly people. Our study aims to simplify the Frailty Index Assessment Scale, while maintaining its reliability and accuracy, to easily and quickly assess frailty in elderly people. In this study, participants (age ≥ 65 years) from the Chinese Longitudinal Healthy Longevity Survey (CLHLS), which had 13,339, 372 and 1214 participants in 2008, 2011, and 2014, respectively, were used. The 2008 dataset was split into 80% for training and 20% for internal validation, and the data from 2011 to 2014 as external validation. In order to obtain effective predictors, we used Lasso regression, Boruta algorithm and random forest classifier score for feature selection. We used six models for predictive model construction and evaluated the models in the validation dataset. Model performance was measured by area under the curve (AUC), accuracy and F1 score. Logistic regression was found to be the best performing and most interpretable algorithm with AUC, accuracy and F1 of 0.974, 0.932 and 0.880 for the validation dataset, respectively. The AUCs for the external independent validation dataset were 0.963 and 0.977, respectively. Subgroup analysis showed that the model had good predictive power in both males and females. The predictive power was stronger among the elderly people over 80 years old, with AUC, accuracy and F1 of 0.973,0.914, and 0.893, respectively. The model also obtained good predictive power in the case of FI measured by different indicators. The model showed good robustness in the follow-up assessment of frailty status in elderly people, with the AUC remaining above 0.95 and accuracy above 0.9 over the long-term follow-up. Using machine learning techniques, we have successfully developed a simple frailty assessment prediction model based on 10 key features to shorten the frailty assessment scale with near full-scale accuracy. A user-friendly website was created to facilitate the application of this prediction model (https://healthy-aging.shinyapps.io/Frailty_Assessment/).

10 March 2025 in International Journal of Behavioral Nutrition and Physical Activity
Verified
Journal Article
Open access
PDF file
LHLi Huang
Li Huang
ZLZHENZHEN LIANG
ZHENZHEN LIANG
HCHuajian Chen
Huajian Chen
Background: Frailty has become an important health problem in the middle-aged and older people population. Physical activity (PA) is a key intervention for frailty prevention and management. However, studies of the association between COVID-19 pre-pandemic PA and the worsening or improvement of frailty during the pandemic remain unclear. Methods: This longitudinal cohort study used data from the English Longitudinal Study of Ageing (ELSA), including participants aged 50 and over. Three intensities of PA (vigorous, moderate, and mild) were categorized as less than once per week and at least once per week, respectively, based on participant self-report. The frailty index (FI) assessed the frailty status, defining frailty as FI ≥ 25. Logistic regression was applied to examine the association between PA and frailty, estimating odds ratios (OR) and 95% confidence intervals (95% CI). Results: Of the 4379 non-frail participants at baseline (median age 67, 54.9% female), 8.1% developed frailty during a mean follow-up of 3.5 years. Among 564 frail participants at baseline (median age 71, 66.5% female), 17.9% regained health. Compared to those engaging in PA less than once per week, participants who engaged in vigorous (OR: 0.47 [95% CI: 0.35–0.62]), moderate (OR: 0.37 [95% CI: 0.29–0.48]), or mild (OR: 0.38 [95% CI: 0.26–0.56]) PA at least once a week had a lower risk of frailty worsening. Additionally, participants who engaged in moderate (OR: 2.04 [95% CI: 1.29–3.21]) or mild (OR: 2.93 [95% CI: 1.54–5.58]) PA at least once a week had a higher likelihood of frailty improvement. Sensitivity analyses based on comprehensive PA levels confirmed these findings. Participants who maintained at least one PA per week had lower frailty worsening (Vigorous, OR: 0.20 [95%CI: 0.12–0.33]; Moderate, OR: 0.13 [95%CI: 0.09–0.19]; Mild, OR: 0.20 [95%CI: 0.11–0.38]) and higher frailty improvement rates (Moderate, OR: 3.43 [95%CI: 1.93–6.11]; Mild, OR: 4.65 [95%CI: 1.90-11.42]). In addition, individuals (Vigorous, OR: 0.35 [95%CI: 0.20–0.60]; Moderate, OR: 0.36 [95%CI: 0.22–0.56]) who transitioned from inactive to active also exhibited a lower risk of frailty. Conclusions: This study emphasized the critical role of PA in preventing and improving frailty in middle-aged and older people, especially during the COVID-19 pandemic. Our study also highlighted the importance of maintaining PA habits to reduce frailty risk and promote its improvement. Also, the study indicated that individuals who transitioned from inactive to active had a lower risk of frailty. These findings enriched the understanding of the association between PA and frailty and provided valuable insights for addressing the health impact of future pandemics on middle-aged and older people.

Verified
Journal Article
Open access
PDF file
QCQiao Chen
Qiao Chen
SQShugen Qu
Shugen Qu
ZLZHENZHEN LIANG
ZHENZHEN LIANG
YLYi Liu
Yi Liu
HCHuajian Chen
Huajian Chen
XLXiaodong Liu
Xiaodong Liu
Despite the wide application of radiotherapy in HCC, radiotherapy efficacy is sometimes limited due to radioresistance. Although radioresistance is reported with high glycolysis, the underlying mechanism between radioresistance and cancer metabolism, as well as the role of cathepsin H (CTSH) within it, remain unclear. In this study, tumor-bearing models and HCC cell lines were used to observe the effect of CTSH on radioresistance. Proteome mass spectrometry, followed by enrichment analysis, were used to investigate the cascades and targets regulated by CTSH. Technologies such as immunofluorescence co-localization flow cytometry and Western blot were used for further detection and verification. Through these methods, we originally found CTSH knockdown (KD) perturbed aerobic glycolysis and enhanced aerobic respiration, and thus promoted apoptosis through up-regulation and the release of proapoptotic factors such as AIFM1, HTRA2, and DIABLO, consequently reducing radioresistance. We also found that CTSH, together with its regulatory targets (such as PFKL, HK2, LDH, and AIFM1), was correlated with tumorigenesis and poor prognosis. In summary, our study found that the cancer metabolic switch and apoptosis were regulated by CTSH signaling, leading to the occurrence of radioresistance in HCC cells and suggesting the potential value of HCC diagnosis and therapy.

19 May 2025 in Social Psychiatry and Psychiatric Epidemiology
Verified
Journal Article
Closed access
PDF file
LHLi Huang
Li Huang
WJWei Jin
Wei Jin
ZLZHENZHEN LIANG
ZHENZHEN LIANG
HCHuajian Chen
Huajian Chen

26 September 2025 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
WJWei Jin
Wei Jin
SLSheng Liu
Sheng Liu
LHLi Huang
Li Huang
XXXi Xiong
Xi Xiong
HCHuajian Chen
Huajian Chen
ZLZHENZHEN LIANG
ZHENZHEN LIANG

23 April 2026 in Oncology Letters
Verified
Journal Article
Open access
PDF file
RZRui Zhang
Rui Zhang
YLYiwen Lu
Yiwen Lu
XFXiaohua Fang
Xiaohua Fang
FZFengquan Zhang
Fengquan Zhang
WWWeidong Wu
Weidong Wu
ZLZHENZHEN LIANG
ZHENZHEN LIANG
Gastrointestinal (GI) cancer remains a leading cause of cancer‑related mortality worldwide, with epigenetic alterations progressively recognized as key drivers of tumorigenesis and therapeutic resistance. Through its role in facilitating cell proliferation, inhibiting apoptosis, driving epithelial‑mesenchymal transition (EMT) and metastasis, reinforcing angiogenesis, inducing metabolic reprogramming, mediating chemoradiotherapy resistance and maintaining cancer stem cell (CSC) properties, protein arginine methyltransferase 5 (PRMT5) has emerged as a key oncogenic regulator among these epigenetic modifiers implicated in GI cancer progression. Elevated PRMT5 expression has been observed in multiple GI cancer subtypes, comprising gastric cancer (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC) and pancreatic cancer, where PRMT5 markedly contributes to tumorigenesis via symmetric dimethylation of histone (e.g., dimethylation of histone H4 at arginine 3) and non‑histone substrates [e.g., AKT1 and sterol regulatory element‑binding protein 1a (SREBP1a)]. In GC, PRMT5 activates the PI3K/AKT pathway [e.g., by methylating AKT1 at arginine (R)391 and upregulating c‑Myc], facilitating tumor cell proliferation and survival. In CRC, PRMT5‑mediated methylation of SMAD4 (e.g., at R361) reinforces TGF‑β signaling, facilitating EMT and metastasis, while its interaction with EGFR further amplifies proliferative signals. PRMT5 also upregulates VEGF expression (e.g., via chromatin remodeling at its promoter), stimulating angiogenesis and inhibits ferroptosis (e.g., by suppressing the solute carrier family 7 member 11/glutathione peroxidase 4 axis in HCC), supporting tumor survival. Furthermore, PRMT5 markedly contributes to metabolic reprogramming (e.g., accelerating de novo lipogenesis via SREBP1a methylation and glycolysis via epigenetic silencing of F‑box and WD repeat domain‑containing protein 7), while strengthening DNA repair (e.g., homologous recombination) and CSC self‑renewal (e.g., via the β‑catenin/IL‑8 axis in CRC) to confer therapy resistance. However, PRMT5 inhibitors (e.g., GSK3326595 and JNJ‑64619178) demonstrate antitumor effects in preclinical models and methylthioadenosine phosphorylase (MTAP) deletion may serve as a potential biomarker for patient selection. The clinical translation of PRMT5 inhibitors is limited by hematological toxicity, lack of robust predictive biomarkers beyond MTAP and potential resistance from compensatory PRMT family members. It is key to clarify GI cancer‑specific PRMT5 mechanisms and potentially develop optimized combination therapies in the future.